PIXITMEDIA
8.7.2022 08:32:05 CEST | Business Wire | Press release
pixitmedia1 , a Kalray company, has announced today that it has been accepted into the Amazon Web Services (AWS) Independent Software Vendor (ISV) Accelerate Program , a co-sell program for AWS Partners who provide software solutions that run on or integrate with AWS. The program helps partners drive new business and accelerate sales cycles by connecting the participating ISVs with the AWS Sales organization.
pixitmedia’s acceptance into the AWS ISV Accelerate program enables the company to meet customer needs through collaboration with the AWS Sales organization. Close collaboration with the AWS Sales team enables pixitmedia to provide better outcomes to AWS customers, as AWS ISV Accelerate Partners and the AWS team work together.
pixitmedia is a trusted solution provider in the Media & Entertainment industry specializing in storage and data management allowing customers to accelerate their journey into the Cloud. The software defined solutions of pixstor and ngenea allow customers to collaborate on a global scale, integrating seamlessly for productions in the cloud. Pixitmedia is a Kalray company (Euronext Growth Paris: ALKAL), a global leader in DPU processors and high-performance computing technologies for data-intensive applications.
The acceptance into the program cements pixitmedia’s position as a valued global AWS partner and industry enabler of cloud-enabled production workflows. pixstor offers AWS customers an agile storage environment that guarantees adaptability and performance, coupled with the power of pixitmedia’s ngenea, that quickly and securely transports data to and from globally distributed cloud, object storage, and traditional NAS files. Together pixitmedia and AWS are a formidable force when servicing creative processes in the cloud.
“Being selected by Amazon Web Services as a member of the ISV Accelerate Program is a strong recognition of our current momentum within the Media & Entertainment Industry. As our products are selected more and more by leading media companies worldwide, we are committed to providing our joint AWS customers ease of use, greater collaboration and seamless workflows. Together we allow customers to realize their creative vision .” Eric Baissus, President and CEO of Kalray.
‘’We are delighted to be part of the ISV Accelerate Program with AWS, to be validated by AWS and recognized as a top partner is testament to the dedication of our teams. We are looking forward to driving more growth and new business whilst delivering the best value and choice for our customers .’’ Paul Cameron, Senior Vice President of Sales, Kalray.
pixitmedia has been working closely with AWS teams across the business. Since joining the APN marketplace in 2021 the company has deployed multiple solutions for joint customers, such as Taylor James, a tag company, Brown Bag Films and Passion Pictures, alongside global Media production and distribution companies. pixitmedia offers solutions for various media workflow challenges such as Efficient Burst Render, Hybrid Workflows, Automated Back-Up and Archive, Cloud Migration, Cloud Studio, On-Demand, Disaster Recovery, True Global Collaboration and Bottomless Storage.
In the past six months, not only has pixitmedia been nominated for the ISV Accelerate Program, but it also qualified for AWS ISV Workload Migration Program (WMP), which helps customers to migrate Independent Storage Vendor (ISV) workloads to Amazon Web Services (AWS) to achieve their business goals and accelerate their cloud journey. Work Migration Program helps pixitmedia to simplify cloud data migration, access, and collaborate processes, thus delivering more efficient and profitable ways of working for its customers. All migrations are delivered through pixitmedia’s trusted partner network and services consultants.
Ben Leaver, EVP Business Development and Co-Founder of pixitmedia
, explains:
“Cloud workflows are woven into the DNA of organizations and have become an engine for productivity, and a driver of digital transformation, particularly in Media & Entertainment Production. The AWS ISV Workload Migration Program allows us to offer organizations the opportunity to extend and lean further into cloud productivity and capitalize on those benefits to remain agile and stay competitive
.”
A POWERFULLY SUCCESSFUL FUTURE
This news also follows pixitmedia’s recent certification as an AWS Technology Partner in the AWS Partner Network, the global community of consulting and technology partners who leverage AWS to build trusted solutions and services for customers. This further cements the company’s position as a valued global AWS partner and industry enabler of cloud-enabled production workflows. To learn more about pixitmedia and AWS solutions and the requirements and benefits of the AWS ISV Accelerate Program contact marketing@pixitmedia.com
.
ABOUT PIXITMEDIA
pixitmedia is a Kalray company (Euronext, ALKAL), a leading provider in the new generation of processors and acceleration cards specialized in Intelligent Data Processing from cloud to Edge. pixitmedia and Kalray share a common vision and a complementary value proposition in both software and hardware to address today’s and tomorrow data-intensive world with solutions for a more intelligent, effective, energy-wise and user-friendly data-driven world.
pixitmedia facilitates seamless collaboration to enable the power of ideas. Our award winning purpose-built, software-defined storage and data solutions simplify the flow of data to connect an increasingly complex world. Our aim is to deliver beyond expectations throughout all areas of our operation. We devise optimized solutions that give customers both choice and freedom, our restless innovation constantly pushes boundaries and the unrivalled care and knowledge of our team ensure optimum performance and value. Customer success is at the heart of our business, we have technical specialists and a unique, dedicated lab facility to guarantee the effectiveness of our solutions. For more information, please visit https://pixitmedia.com or contact us: marketing@pixitmedia.com
ABOUT KALRAY
Kalray (Euronext Growth Paris - FR0010722819 - ALKAL) is a fabless semiconductor company, a leading provider of a new class of processors, specialized in Intelligent Data Processing from Cloud to Edge. Kalray’s team have created and developed its leading-edge technology and products to help its clients maximize the market possibilities presented by a world dominated by massive, disparate and pervasive data.
Thanks to Kalray’s patented manycore architecture, Kalray’s MPPA® Intelligent Data Processors are natively capable of managing multiple workloads with no bottlenecks to enable smarter, more efficient and energy-wise data-intensive applications. Kalray's offering includes processors, acceleration cards with associated software environment and appliances, allowing its customers to design the best solutions in fast growing sectors such as modern data centers, 5G, AI and Edge Computing, autonomous vehicles and others.
Founded in 2008 as a spin-off of CEA French lab, with investors such as Alliance Venture (Renault-Nissan-Mitsubishi), Safran, NXP Semiconductors, CEA and Bpifrance, Kalray is dedicated through technology, expertise and passion to offer more: More for a smart world, more for the planet, more for customers and developers. www.kalrayinc.com
1 pixitmedia is the dedicated branch for Media & Entertainment markets of Arcapix Holdings Ltd, acquired by Kalray. See press release on March 3, 2022 .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220707005593/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom